Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07637071

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

Conditions: Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning

Sex: Male
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: NA
Enrollment: 48
Sponsor: Restore Biologics Holdings, Inc. dba Xtressé

Location: Advanced Dermatology & Cosmetic Surgery Maitland Florida

Summary

The goal of this study is to determine if Xtresse' gummy is safe and may help regrow hair in men with androgenic alopecia (common pattern hair loss). Forty-eight participants will be randomly assigned to receive either Xtresse' active gummy or placebo. Neither staff not participant will know which treatment is given. The main aims of this trial are: 1. To confirm using photographic analysis, changes in the quality, volume, and thickness of hair. 2. To gauge patient satisfaction with hair changes and application process. 3. Monitor and report any adverse events associated with the daily intake of Xtressé Participants who qualify will complete 3 in-person visits. Participants will be given a 90-day supply of the gummies at visits 1 (after voluntary consent is given) and 2 to cover the 6-month study period. Photographs and scalp analysis will be performed at each visit to measure changes in hair volume, thickness, and growth.

Eligibility Criteria

Inclusion Criteria: * Males aged 18-65 * Norwood III to IV, vertex focused * Fitzpatrick skin type I to VI * Ability and willingness to comply with study protocol Exclusion Criteria: * Change in other hair treatments in 3 months prior to study enrollment. * Known uncontrolled health conditions. * History of hair or scalp disorders that could interfere with study results. * History of metabolic syndrome.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07637071). StuddyBuddy aggregates publicly available trial information.